Becker's Healthcare December 2, 2025
Access to GLP-1 medications for weight loss through ACA marketplace plans is shrinking, according to a new analysis from healthcare advisory group Leverage|Axiaci shared with Becker’s.
The analysis was conducted with funding from the Robert Wood Johnson Foundation. Leverage|Axiaci reviewed the policies of the 300 carriers offering marketplace plans in 2026 to determine the coverage and conditions of coverage for three GLP-1 drugs, Wegovy, Zepbound, and Saxenda.
Six notes:
1. GLP-1 coverage for weight loss declined from 3.6 million enrollees in 2024 to 2.8 million in 2026.
2. If the same 24.5 million people enrolled in ACA plans in 2025 were re-enrolled in 2026, less than 10% would have coverage, and a fraction of those individuals would meet the...
Today's Sponsors
Today's Sponsor